ALTANIB® nova 400

ALTANIB® nova 400 is a targeted prescription antineoplastic medication containing Imatinib (400 mg). Classified as a tyrosine kinase inhibitor, it works by blocking the action of abnormal proteins that signal cancer cells to multiply, effectively halting or slowing disease progression. It is primarily indicated for treating adults and pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It is also prescribed for Ph+ acute lymphoblastic leukemia, myelodysplastic/myeloproliferative diseases, and gastrointestinal stromal tumors (GIST). This potent oral therapy requires strict adherence and continuous management under a specialized oncologist.